Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs

 Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs  -Bebeau Brings Her Extensive Experience in Managing Cardiac Device Clinical  Programs to the Tiara™ and Neovasc Reducer™ New Product Programs-  -New Clinical Initiatives for Tiara and the Neovasc Reducer Targeted for 2014  and 2015- TSX Venture Exchange: NVC  VANCOUVER, May 8, 2014 /CNW/ - Neovasc Inc. (TSXV: NVC) (the 'Company' or  'Neovasc') today announced that Vicki Bebeau has joined the company in the  role of Vice President, Clinical Affairs, a newly-created position. Ms. Bebeau  brings Neovasc more than 18 years of experience in clinical trial planning and  management at industry leaders St. Jude Medical, Boston Scientific and  Medtronic.  "With the ongoing successes of our Tiara™ mitral valve and Neovasc  Reducer™ programs, Neovasc is preparing to undertake clinical trial  initiatives for both products," noted Alexei Marko, CEO of Neovasc. "We plan  to initiate multinational feasibility studies for Tiara in late 2014, and we  are targeting a 2015 start for the Reducer clinical program needed for an IDE  approval in the United States."  Mr. Marko added, "These high potential programs are central to our success and  we are delighted to have recruited Vicki Bebeau, a highly experienced industry  veteran, as our head of Clinical Affairs. Ms. Bebeau has held clinical  positions of increasing responsibility at medical device industry leaders St.  Jude Medical, Boston Scientific and Medtronic, where she successfully directed  multinational clinical studies in Canada, the United States, and Europe."  Neovasc is preparing to begin formal clinical feasibility studies for its  Tiara device for the transcatheter treatment of mitral valve disease later  this year. In addition, building on positive results recently reported from  the Reducer COSIRA trial, Neovasc has initiated design of a US-IDE study to  support an application for FDA approval of the Reducer. The study is expected  to begin next year.  "Neovasc has earned a strong reputation in the industry for their development  of novel cardiovascular devices addressing major unmet medical needs, and I  look forward to playing a key role in advancing the clinical programs that are  central to the clinical and commercial success of the Tiara and Reducer new  product programs," commented Ms. Bebeau.  Neovasc intends to continue the expansion of its clinical team and related  operations to support the Tiara and Reducer product programs.  About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and  markets products for the rapidly growing cardiovascular marketplace. Its  products include the Tiara™ technology in development for the transcatheter  treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of  refractory angina and a line of advanced biological tissue products that are  used as key components in third-party medical products including transcatheter  heart valves. For more information, visit www.neovasc.com  Statements contained herein that are not based on historical or current fact,  including without limitation statements containing the words "anticipates,"  "believes," "may," "continues," "estimates," "expects," "forecasts",  "targets", and "will" and words of similar import, constitute "forward-looking  statements" within the meaning of the U.S. Private Securities Litigation  Reform Act of 1995. Such forward looking statements, including the forecasted  start date for the formal clinical feasibility studies of the Tiara and the  targeted FDA approval application for the Reducer, involve known and unknown  risks, uncertainties and other factors that may cause the actual results,  events or developments to be materially different from any future results,  events or developments expressed or implied by such forward-looking  statements. Such factors include, among others, the following: general  economic and business conditions, both nationally and in the regions in which  the Company operates; history of losses and lack of and uncertainty of  revenues, ability to obtain required financing, receipt of regulatory approval  of product candidates, ability to properly integrate newly acquired  businesses, technology changes; competition; changes in business strategy or  development plans; the ability to attract and retain qualified personnel;  existing governmental regulations and changes in, or the failure to comply  with, governmental regulations; liability and other claims asserted against  the Company; and other factors referenced in the Company's filings with  securities regulators. Although the Company believes that expectations  conveyed by the forward-looking statements are reasonable based on the  information available to it on the date such statements were made, no  assurances can be given as to the future results, approvals or achievements.  Given these uncertainties, readers are cautioned not to place undue reliance  on such forward-looking statements. The Company does not assume the obligation  to update any forward-looking statements except as otherwise required by  applicable law.    SOURCE  Neovasc Inc.  Corporate Contact: Chris Clark Neovasc Inc. 604 248-4138 cclark@neovasc.com  U.S. Media & investor Contact: BLL Partners, LLC Barbara Lindheim 212 584-2276   blindheim@bllbiopartners.com  To view this news release in HTML formatting, please use the following URL:  http://www.newswire.ca/en/releases/archive/May2014/08/c7311.html  CO: Neovasc Inc. ST: British Columbia NI: MTC 2575 WNEWS